We are live on ! Find out more
RCUS icon

Arcus Biosciences
RCUS

172 hedge funds and large institutions have $997M invested in Arcus Biosciences in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 61 increasing their positions, 59 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more call options, than puts

Call options by funds: $5.35M | Put options by funds: $3.19M

3% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 59

2% less capital invested

Capital invested by funds: $1.02B → $997M (-$25.2M)

7% less funds holding

Funds holding: 185 → 172 (-13)

13.37% less ownership

Funds ownership: 71.53% → 58.16% (-13%)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

39% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 31

Holders
172
Holders Change
-13
Holders Change %
-7.03%
% of All Funds
2.48%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
19
Increased
61
Reduced
59
Closed
31
Calls
$5.35M
Puts
$3.19M
Net Calls
+$2.16M
Net Calls Change
-$5.09M

Top Buyers

1
WP
Woodline Partners
California
+$31.9M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$19.8M
3
State Street
State Street
Massachusetts
+$11.5M
4
LCM
Laurion Capital Management
New York
+$9.47M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$3.43M

Top Sellers

1
OCA
Octagon Capital Advisors
New York
-$35.7M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$9.85M
3
Morgan Stanley
Morgan Stanley
New York
-$9.13M
4
Ameriprise
Ameriprise
Minnesota
-$7.5M
5
Pictet Asset Management
Pictet Asset Management
Switzerland
-$6.78M
Name Holding Trade Value Shares
Change 		Change in
Stake
Citigroup
26
Citigroup
New York
$5.97M +$3.27M +188,896 +148%
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$5.95M +$3.43M +198,274 +170%
GIM
28
Granahan Investment Management
Massachusetts
$5.6M +$1.14M +65,793 +29%
Principal Financial Group
29
Principal Financial Group
Iowa
$5.47M -$741K -42,849 -13%
Two Sigma Investments
30
Two Sigma Investments
New York
$4.97M +$2.6M +150,204 +133%
PHP
31
Parkman Healthcare Partners
Connecticut
$4.91M +$212K +12,256 +5%
Nordea Investment Management
32
Nordea Investment Management
Sweden
$4.89M +$933K +53,944 +26%
Goldman Sachs
33
Goldman Sachs
New York
$4.73M -$5.91M -341,978 -58%
Renaissance Technologies
34
Renaissance Technologies
New York
$4.54M +$2.02M +117,000 +95%
EAM
35
Eventide Asset Management
Massachusetts
$4.53M – – –
Axa
36
Axa
France
$4.38M +$1.09K +63 +0%
DCM
37
DAFNA Capital Management
California
$4.37M -$17.3K -1,000 -0.4%
UBS Group
38
UBS Group
Switzerland
$3.94M +$800K +46,245 +28%
PIM
39
Platinum Investment Management
Australia
$3.86M – – –
Invesco
40
Invesco
Georgia
$3.6M -$33.7K -1,947 -1%
Barclays
41
Barclays
United Kingdom
$3.55M -$260K -15,022 -7%
GGHC
42
Gilder Gagnon Howe & Co
New York
$3.3M +$614K +35,485 +25%
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
$3.26M +$23.1K +1,335 +0.8%
Hudson Bay Capital Management
44
Hudson Bay Capital Management
Connecticut
$3.12M -$86.5K -5,000 -3%
Legal & General Group
45
Legal & General Group
United Kingdom
$2.84M +$22.9K +1,322 +0.9%
Bank of America
46
Bank of America
North Carolina
$2.82M -$265K -15,340 -9%
N
47
Nuveen
North Carolina
$2.4M -$108K -6,228 -5%
Public Sector Pension Investment Board (PSP Investments)
48
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$2.11M – – –
SSA
49
Schonfeld Strategic Advisors
New York
$1.96M -$2.2M -126,960 -55%
New York State Teachers Retirement System (NYSTRS)
50
New York State Teachers Retirement System (NYSTRS)
New York
$1.88M – – –
1
2
3 4 5

RCUS Hedge Fund Activity: Q1 2024 in Review

172 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q1 2024, worth a combined $997M — down 2.5% from $1.02B a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of RCUS and 19 opened new positions — a net loss of 12 holders — while 59 trimmed existing stakes and 61 added.

The largest buyer was Woodline Partners, adding an estimated $31.9M. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $35.7M sold.

  • 172 institutional investors held Arcus Biosciences (RCUS) as of Q1 2024, down from 185 in Q4 2023.
  • Funds reported $997M of Arcus Biosciences stock for Q1 2024, down 2.5% quarter-over-quarter.
  • 19 funds opened new Arcus Biosciences positions in Q1 2024 and 31 closed out, a net change of -12 holders.
  • The largest Arcus Biosciences buyer in Q1 2024 was Woodline Partners, an estimated $31.9M added.
  • The largest Arcus Biosciences seller in Q1 2024 was Octagon Capital Advisors, an estimated $35.7M sold.

Based on aggregated 13F filings for Q1 2024.